IF＞130！ Ophthalmologist Tao Yong has published a total of 13 articles in 2024

陶勇,IF

z-bio

2025-02-21

603

　　In January 2020, Dr. Tao Yong was violently attacked during a visit to Chaoyang Hospital in Beijing, resulting in a serious injury to his left hand and even having to temporarily leave the clinical front line.

　　However, over the years, Dr. Tao Yong has been tirelessly working on the front line of scientific research, demonstrating with practical actions what true medical compassion truly means.

　　Whether on the operating table or in the laboratory, he constantly explores new fields of ophthalmic medicine with unparalleled passion and professionalism, committed to bringing more hope and light to patients.

　　In 2024, Dr. Tao Yong's research journey can be described as fruitful, with more than ten SCI papers successfully published online. We have selected some articles for display, let's take a look together ↓↓↓

　　The first NEJM (IF=96.2)

　　On January 20, 2024, Dr. Tao Yong and Dr. Zhang Tao from Beijing Chaoyang Hospital affiliated with Capital Medical University jointly published a case report titled "Hemolacria" in The New England Journal of Medicine.

　　This case report provides a detailed record of the clinical symptoms of a rare blood tear syndrome, systematically describing its pathogenesis, clinical characteristics, and diagnostic and treatment methods. This case provides valuable diagnostic insights for ophthalmologists and emergency department doctors, and suggests that when encountering similar patients, the possibility of blood reflux to the lacrimal system after nosebleeds treatment should be considered.

　　The second article is Adv. Healthcare Mater (IF=10)

　　On October 23, 2024, Dr. Tao Yong's team published an article titled "In Situ Crystallized Ceria Vesicle Nanohybrid Therapy for Effective Treatment of Inflammatory Intraocular Disease".

　　Posterior uveitis can lead to severe visual impairment, with oxidative stress exacerbating inflammation and forming a continuous cycle of damage, which current treatments can only temporarily alleviate. This study developed a novel treatment method, which involves in situ crystallization of ultra small cerium oxide nanoparticles (approximately 3 nanometers) on extracellular vesicles (EVs) of mesenchymal stem cells (MSCs) for the treatment of sensitized mycobacterial uveitis (PMU). This nanocomposite material utilizes the independent and synergistic effects of its components to provide a comprehensive treatment plan.

　　Chapter 3: J.Infect. Dis. (IF=5)

　　On January 12, 2024, Dr. Tao Yong's team published an article titled "Performance of Metagenomic Next Generation Sequestration of Cell Free DNA from Vitreous and Aquatic Humor for Diagnoses of Intraocular Infections".

　　Delayed diagnosis and inappropriate treatment of intraocular infections often lead to poor prognosis. Due to the limitations of traditional cultivation and PCR methods, most pathogens cannot be identified. This study demonstrates the potential of using metagenomic next-generation sequencing (mNGS) technology for rapid and accurate diagnosis of suspected intraocular infection patients. Through analysis of cell-free DNA in vitreous and aqueous humor samples from 488 patients, it was found that mNGS not only improves the sensitivity and accuracy of pathogen identification compared to traditional diagnostic methods, but is also particularly suitable for small volume samples. Moreover, mNGS using vitreous humor samples showed slightly better sensitivity and diagnostic accuracy than aqueous humor samples, providing new directions and technical support for the diagnosis of intraocular infections in the future.

　　The Fourth Frontier Pharmacol.（IF=4.4）

　　On August 9, 2024, Dr. Tao Yong's team published an article titled "Adverse event reporting of the IGF-1R monoclonal antibody tepotumumab: a real-world study based on the US food and drug administration adverse event reporting system".

　　This study conducted a detailed exploration of adverse events that occurred during the treatment of thyroid eye disease with trastuzumab by analyzing data from the FDA's adverse event reporting system. Research has found that the use of trastuzumab may lead to various adverse events, particularly musculoskeletal problems, fatigue, tinnitus, and most reports come from female patients. These findings provide important information for the safer use of trastuzumab in clinical practice, and also contribute to the further development of the drug and its promotion in the global market.

　　Chapter 5: Heliyon (IF=3.4)

　　On June 28, 2024, Dr. Tao Yong's team published a case report titled "Recurrent lacrimal glass adenoid cystic carcinoma: A case report and literature review" in Heliyon.

　　Adenoid cystic carcinoma of the lacrimal gland (LGACC) is known for its high recurrence rate, tendency towards nerve invasion, and distant metastasis, leading to poor prognosis for patients. This case report provides a detailed description of the diagnosis and treatment of the disease.

　　In the case, a 34 year old male patient presented with persistent symptoms of left eye protrusion for 4 months. After imaging examination, it was highly suspected to be LGACC, and the diagnosis was confirmed through eye conserving orbital tumor resection surgery. Although postoperative radiation therapy was recommended, the patient refused to accept it, resulting in tumor recurrence within 3 months after surgery. Eventually, more aggressive orbital contents removal surgery had to be performed, and pathological results showed poorly differentiated LGACC. Subsequently, the patient followed the doctor's advice and received radiation therapy, but within less than a year, intracranial metastasis occurred.

　　This case highlights the difficulty in early diagnosis of LGACC due to its insidious onset and lack of specific symptoms, as well as its tendency to recur and metastasize. It emphasizes the need for early diagnosis, active treatment strategies, and strict adherence to postoperative adjuvant therapy to improve patient prognosis. Future research should focus on a deeper understanding of the pathogenesis of LGACC and strive to develop standardized diagnosis and treatment plans to improve patients' survival rates and quality of life.